1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 

Slides:



Advertisements
Similar presentations
Depression in adults with a chronic physical health problem
Advertisements

COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Justice and Economic Evaluation Prof. Dr. Jan Busschbach
Sharing the diagnosis of dementia Alistair Burns Manchester Mental Health and Social Care Trust University of Manchester Manchester Academic Health Science.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
A brief introduction to EuroQol Group Foundation.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
The Importance of Decision Analytic Modelling in Evaluating Health Care Interventions Mark Sculpher Professor of Health Economics Centre for Health Economics.
Advance Care Planning Regina Mc Quillan. Advance care planning What? Who? Why? When? Where?
Optimizing care for patients with OA 111 Joost Dekker PhD Department of Rehabilitation Medicine & Department of Psychiatry VU University Medical Center,
Genetic testing By: Bronwyn Peat. What is genetic testing?  Genetic Testing: it is a test that involves taking a sample from someone’s blood, hair, skin.
QALYs and Ethics Prof. dr. Jan van Busschbach 11.
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
QALYs and Ethics Is there an ethical / valid alternative?
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
Indianapolis Discovery Network for Dementia Forecasting the Future Impact of Early Detection and Management Program for Alzheimer.
Talking Points for Managers Community Initiative on Depression Mid-America Coalition on Health Care.
Kevin Mullins National IAPT Director IAPT Programme Origins & Status December 2014.
Cost-Effectiveness Thresholds Professor of Health Economics
BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
TRAP: A long term outcome and process study of a residential treatment for treatment refractory adolescents with personality disorders Dineke Feenstra.
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
Introduction: Medical Psychology and Border Areas
1 Monitoring Quality of Life in the Clinic Prof. dr. Jan van Busschbach Medical Psychology and Psychotherapy Erasmus MC.
Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
Introduction to workshop by Erasmus MC and EUR about Identity and Impact for researchers and PH-D students KNVI O&O Presentation – Thursday, June 18 th.
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
1 The Economic Burden of Personality Disorders  Djøra Soeteman, Jan J.V. Busschbach, Leona Hakkaart-van Roijen, Roel Verheul  Viersprong Institute for.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
11 Cost Effectiveness in Preventing Crime  Jan van Busschbach, Djøra Soeteman  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
Implementing NICE guidance 2011 NICE clinical guideline 113 Generalised anxiety disorder in adults.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Cost Effectiveness  Jan J.V. Busschbach, Ph.D.  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Introduction to Healthcare and Public Health in the US The Evolution and Reform of Healthcare in the US Lecture b This material (Comp1_Unit9b) was developed.
WHAT IS HEALTH ECONOMICS? ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ ACCOUNTANTS CARE ONLY ABOUT $$$$$$$$$$ PHYSICIANS CARE ONLY ABOUT PATIENTS…… PHYSICIANS.
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Economic Impact of An Integrated Behavioral Health Program Kenneth Kushner, PhD Professor, University of Wisconsin Department of Family Medicine Neftali.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Managing Pediatric Obesity: The benefits of implementing training interventions and obesity- specific education to primary care providers. Racquel Praino.
Using Outcomes and other Assessment Tools to Improve Quality Quality Improvement.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
A pragmatic cluster randomised controlled trial of a complex ward-based intervention on antipsychotic polypharmacy prescribing in adult psychiatric inpatient.
REINHARD HEUN PROFESSOR OF PSYCHIATRY RADBOURNE UNIT RDH DERBYSHIRE HEALTHCARE FT KEGWORTH, 1 APRIL 2014 What works well in the treatment of psychosis.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
Barriers for implementing drug holidays in ADHD
The introduction of a routine offer of relapse prevention pharmacotherapy following successful alcohol withdrawal: A quality improvement project in a 20.
WHAT IS HEALTH ECONOMICS?
Nat. Rev. Cardiol. doi: /nrcardio
Severe Chronic Conditions Substantial Service Needs
Diagnosis Stage Parkinson’s Disease (PD) Guidelines
Treatment-Resistant Schizophrenia
Justification treatment cost
Distribution of total possible savings (y-axis), showing how much total saving there would be if only those over £x per practice per month (x-axis) were.
Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.
Presentation transcript:

1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam,  

2 Cost Effectiveness  Cost  Effects  Cost / Effects QALY League table

3 Rare formal CE research  Cost Effectiveness (CE) research focuses on:  New pharmaceutical Guidelines NICE / CvZ  New high cost technical innovations Hip fractions  For most common interventions no data  Wheel chair, home care, visits to family doctors…  Intervention in Personality Disorder are no exception  New initiatives in PD  University of Maastricht  De Viersprong (UvA, Erasmus MC)

4 What doe we know?  Effects can be considerable  Personality Disorder can be treated successfully  Effect are generic  Cost can be high  As a complex psychological intervention has to be implemented  Savings in other area's are likely As with all intensive treatments..

5 Effects

6 Direct costs STIP  STIP  Short-Term Inpatient Psychotherapy  Cost price  Per patient day: €  3 mouths = 91.3 day  91.3 x 210 = 19, €

7 The economic burden of personality disorders  Possible savings  Soeteman, et al.  Submitted to Journal of Clinical Psychiatry  Direct Medical costs before treatment  Total € 7397

8 Productivity losses

9 Savings  Savings might outweighed costs  Gabber et al.  Review 1997, AJP

10 QALY League table

11 Only cost effectiveness?

12 Burden of disease Soeteman et al, 2007 The burden of disease in personality disorders: diagnosis- specific quality of life. Accepted for publication in the Journal of Personality Disorder

13 Conclusion  Formal cost effectiveness data is lacking  Is on it way…  Costs are high  Savings are likely  Effects are substantial  The cost effectiveness is therefore likely to be reasonable  A cost effective treatment for a disease with a considerable burden